SCHEDULE: Vanguard Group's 10% Stake in Amicus Therapeutics
Beneficial Ownership Disclosure
The Vanguard Group reported a 10% beneficial ownership stake in Amicus Therapeutics Inc. common stock as of November 28, 2025.
Summary
- The Vanguard Group reported beneficial ownership of 30,871,374 shares of Amicus Therapeutics Inc. common stock.
- This represents 10% of the class of securities.
- The filing is an Amendment No. 8 to Schedule 13G.
- Vanguard holds sole dispositive power over 28,380,963 shares and shared dispositive power over 2,490,411 shares.
- Vanguard holds shared voting power over 2,120,104 shares and no sole voting power.
Sentiment
Score: 5
Explanation: Neutral, as this is a routine regulatory filing disclosing passive ownership by an institutional investor. It doesn't inherently convey positive or negative sentiment about the issuer's performance, but a large institutional stake can be seen as a baseline vote of confidence.
Positives
- A major institutional investor, The Vanguard Group, holds a significant 10% stake, which can be interpreted as a vote of confidence in Amicus Therapeutics Inc.'s long-term viability.
Negatives
- No specific negative information about Amicus Therapeutics Inc. is disclosed in this passive ownership filing.
Risks
- No specific risks related to Amicus Therapeutics Inc. are disclosed in this passive ownership filing.
Future Outlook
Not applicable as this filing pertains to beneficial ownership disclosure by an institutional investor and does not contain forward-looking statements from the issuer.
Industry Context
The disclosure of a 10% stake by a major passive institutional investor like Vanguard is a routine regulatory filing. It reflects Vanguard's strategy of broad market exposure through its various funds, rather than a specific strategic move related to Amicus Therapeutics' industry position or competitive landscape.
Stakeholder Impact
- Shareholders: The presence of a large, passive institutional investor like Vanguard can provide stability and liquidity to the stock.
- Company Management: Awareness of a significant institutional holder may influence corporate governance considerations, though Vanguard's role is typically passive.
Key Dates
| Date | Description |
|---|---|
| 11/28/2025 | Date of event requiring the filing of this statement |
| 12/03/2025 | Date of filing |
Keywords
Vanguard Group, Amicus Therapeutics, Common Stock, Institutional Ownership, Schedule 13G, Beneficial Ownership, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.